{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T13:58:57Z","timestamp":1784383137285,"version":"3.55.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003030","name":"AGAUR","doi-asserted-by":"publisher","award":["SGR 01324 Q5856414G"],"award-info":[{"award-number":["SGR 01324 Q5856414G"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["ICI21\/00103"],"award-info":[{"award-number":["ICI21\/00103"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["RH RH042953"],"award-info":[{"award-number":["RH RH042953"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["CM23\/00277"],"award-info":[{"award-number":["CM23\/00277"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["RH RH042953"],"award-info":[{"award-number":["RH RH042953"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Iberoamericana de Micolog\u00eda"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.riam.2025.01.005","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T01:07:57Z","timestamp":1742605677000},"page":"51-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Experience with isavuconazole in the treatment of mucormycosis and breakthrough fungal infections"],"prefix":"10.1016","volume":"42","author":[{"given":"Carolina","family":"Garcia-Vidal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gallardo-Pizarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso Francesco","family":"Aiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Martinez-Urrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Teijon-Lumbreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Monzo-Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.riam.2025.01.005_bib0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jof9020166","article-title":"Comparing the real-world use of isavuconazole to other anti-fungal therapy for invasive fungal infections in patients with and without underlying disparities: a multi-center retrospective study","volume":"9","author":"Batista","year":"2023","journal-title":"J Fungi"},{"key":"10.1016\/j.riam.2025.01.005_bib0110","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1086\/430710","article-title":"Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer","volume":"41","author":"Chamilos","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2025.01.005_bib0115","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/myc.12960","article-title":"Defining breakthrough invasive fungal infection \u2013 position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology","volume":"62","author":"Cornely","year":"2019","journal-title":"Mycoses"},{"key":"10.1016\/j.riam.2025.01.005_bib0120","first-page":"e24932","article-title":"Pulmonary mucormycosis in a poorly controlled diabetic patient","volume":"14","author":"Duarte","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.riam.2025.01.005_bib0125","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/TP.0000000000004312","article-title":"Isavuconazole for the treatment of invasive mold disease in solid organ transplant recipients: a multicenter study on efficacy and safety in real-life clinical practice","volume":"107","author":"Fern\u00e1ndez-Ruiz","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/j.riam.2025.01.005_bib0130","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1128\/CMR.00056-10","article-title":"Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species","volume":"24","author":"Gomes","year":"2011","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.riam.2025.01.005_bib0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jof8030258","article-title":"A clustered case series of Mucorales detection in respiratory samples from COVID-19 patients in intensive care, France, August to September 2021","volume":"8","author":"Guemas","year":"2022","journal-title":"J Fungi"},{"key":"10.1016\/j.riam.2025.01.005_bib0140","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/myc.13148","article-title":"Breakthrough invasive fungal infections: who is at risk?","volume":"63","author":"Jenks","year":"2020","journal-title":"Mycoses"},{"key":"10.1016\/j.riam.2025.01.005_bib0145","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cmi.2018.07.011","article-title":"The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports","volume":"25","author":"Jeong","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.riam.2025.01.005_bib0150","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1086\/512817","article-title":"Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: a hypothesis","volume":"44","author":"Kontoyiannis","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2025.01.005_bib0155","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.mmcr.2021.03.005","article-title":"Successful treatment of Rhizopus arrhizus rhino-orbital-cerebral mucormycosis with isavuconazole salvage therapy following extensive debridement","volume":"32","author":"Miller","year":"2021","journal-title":"Med Mycol Case Rep"},{"key":"10.1016\/j.riam.2025.01.005_bib0160","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/cid\/ciab1066","article-title":"Evaluation of serum Mucorales polymerase chain reaction (PCR) for the diagnosis of mucormycoses: the MODIMUCOR prospective trial","volume":"75","author":"Millon","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2025.01.005_bib0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijid.2024.107070","article-title":"Safety and effectiveness of isavuconazole in real-life non-neutropenic patients","volume":"144","author":"Monz\u00f3-Gallo","year":"2024","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.riam.2025.01.005_bib0170","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1007\/s40121-024-01064-4","article-title":"Effectiveness, safety, and patterns of real-world isavuconazole use in Europe (2015\u20132019)","volume":"13","author":"Neofytos","year":"2024","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.riam.2025.01.005_bib0175","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.transproceed.2024.07.005","article-title":"Risk factors and outcomes of Mucorales infection in a modern cohort of solid organ transplant, hematopoietic cell transplant, and chimeric antigen receptor T-cell therapy recipients","volume":"56","author":"Ogawa","year":"2024","journal-title":"Transplant Proc"},{"key":"10.1016\/j.riam.2025.01.005_bib0180","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jinf.2023.05.005","article-title":"Breakthrough invasive fungal infection among patients with haematologic malignancies: a national, prospective, and multicentre study","volume":"87","author":"Puerta-Alcalde","year":"2023","journal-title":"J Infect"},{"key":"10.1016\/j.riam.2025.01.005_bib0185","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1128\/CMR.13.2.236","article-title":"Zygomycetes in human disease","volume":"13","author":"Ribes","year":"2000","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.riam.2025.01.005_bib0190","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: a review of 929 reported cases","volume":"41","author":"Roden","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2025.01.005_bib0195","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1128\/AAC.49.2.830-832.2005","article-title":"Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice","volume":"49","author":"Spellberg","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2025.01.005_bib0200","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/cid\/ciw305","article-title":"Isavuconazole treatment of cryptococcosis and dimorphic mycoses","volume":"63","author":"Thompson","year":"2016","journal-title":"Clin Infect Dis"}],"container-title":["Revista Iberoamericana de Micolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130140625000166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130140625000166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T18:00:24Z","timestamp":1762365624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130140625000166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1130140625000166"],"URL":"https:\/\/doi.org\/10.1016\/j.riam.2025.01.005","relation":{},"ISSN":["1130-1406"],"issn-type":[{"value":"1130-1406","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Experience with isavuconazole in the treatment of mucormycosis and breakthrough fungal infections","name":"articletitle","label":"Article Title"},{"value":"Revista Iberoamericana de Micolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.riam.2025.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Asociaci\u00f3n Espa\u00f1ola de Micolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}